Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Depreciation and Depletion (2018 - 2024)

Bicycle Therapeutics (BCYC) has disclosed Depreciation and Depletion for 7 consecutive years, with $1.6 million as the latest value for Q2 2024.

  • For the quarter ending Q2 2024, Depreciation and Depletion changed 0.0% year-over-year to $1.6 million, compared with a TTM value of $6.6 million through Jun 2024, up 11.86%, and an annual FY2023 reading of $6.5 million, up 75.68% over the prior year.
  • Depreciation and Depletion was $1.6 million for Q2 2024 at Bicycle Therapeutics, down from $1.7 million in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $1.7 million in Q3 2023 and bottomed at $300000.0 in Q1 2020.
  • Average Depreciation and Depletion over 5 years is $900000.0, with a median of $500000.0 recorded in 2020.
  • The sharpest move saw Depreciation and Depletion changed 0.0% in 2020, then surged 333.33% in 2022.
  • Year by year, Depreciation and Depletion stood at $400000.0 in 2020, then changed by 0.0% to $400000.0 in 2021, then soared by 250.0% to $1.4 million in 2022, then grew by 14.29% to $1.6 million in 2023, then changed by 0.0% to $1.6 million in 2024.
  • Business Quant data shows Depreciation and Depletion for BCYC at $1.6 million in Q2 2024, $1.7 million in Q1 2024, and $1.6 million in Q4 2023.